Ivan Bilic - Publications

Second primary malignancies in neuroendocrine tumors: a single-center cohort study.

Journal: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)

Published: April 11, 2026

Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment-A Case Report.

Journal: Current oncology (Toronto, Ont.)

Published: March 18, 2026

The development of local outpatient palliative care referral criteria for persons with advanced cancer at the University Hospital Centre Zagreb: a Delphi study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: September 25, 2025

Impact of anthracycline-based chemotherapy on RB1 gene methylation in peripheral blood leukocytes and biomarkers of oxidative stress and inflammation in sarcoma patients.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 20, 2023

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?

Journal: Pharmacogenomics

Published: January 13, 2023

DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.

Journal: British journal of clinical pharmacology

Published: September 03, 2021

Breast metastasis as the initial presentation of malignant pleural mesothelioma.

Journal: The breast journal

Published: May 06, 2020

Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.

Journal: Acta dermatovenerologica Croatica : ADC

Published: May 06, 2016

The Most Common Cutaneous Side Effects of Epidermal Growth Factor Receptor Inhibitors and Their Management.

Journal: Acta dermatovenerologica Croatica : ADC

Published: January 04, 2016